View ValuationUBI Pharma 将来の成長Future 基準チェック /06現在、 UBI Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長31.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Apr 20Full year 2023 earnings released: EPS: NT$0.01 (vs NT$0.41 in FY 2022)Full year 2023 results: EPS: NT$0.01 (down from NT$0.41 in FY 2022). Revenue: NT$648.6m (up 2.3% from FY 2022). Net income: NT$803.0k (down 98% from FY 2022). Profit margin: 0.1% (down from 7.4% in FY 2022). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Apr 18Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$22.80, the stock trades at a trailing P/E ratio of 64.6x. Average trailing P/E is 48x in the Biotechs industry in Taiwan. Total loss to shareholders of 45% over the past year.New Risk • Apr 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.20b (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (NT$3.20b market cap, or US$98.5m).お知らせ • Mar 20UBI Pharma Inc., Annual General Meeting, Jun 06, 2024UBI Pharma Inc., Annual General Meeting, Jun 06, 2024.New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).New Risk • Dec 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).Reported Earnings • Aug 17First half 2023 earnings released: EPS: NT$0.12 (vs NT$0.18 in 1H 2022)First half 2023 results: EPS: NT$0.12 (down from NT$0.18 in 1H 2022). Revenue: NT$335.7m (up 5.2% from 1H 2022). Net income: NT$13.8m (down 28% from 1H 2022). Profit margin: 4.1% (down from 6.1% in 1H 2022). The decrease in margin was driven by higher expenses.New Risk • Aug 12New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.4% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.Buying Opportunity • Jul 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be NT$44.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.Buying Opportunity • Jun 16Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 22%. The fair value is estimated to be NT$44.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.Reported Earnings • Apr 22Full year 2022 earnings released: EPS: NT$0.43 (vs NT$0.23 in FY 2021)Full year 2022 results: EPS: NT$0.43 (up from NT$0.23 in FY 2021). Revenue: NT$633.8m (down 1.6% from FY 2021). Net income: NT$47.2m (up 111% from FY 2021). Profit margin: 7.4% (up from 3.5% in FY 2021). The increase in margin was driven by lower expenses.Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$55.60, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 40x in the Biotechs industry in Taiwan. Total returns to shareholders of 509% over the past three years.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Yau-Huei Wei was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improved over the past weekAfter last week's 25% share price gain to NT$39.40, the stock trades at a trailing P/E ratio of 54.2x. Average trailing P/E is 35x in the Biotechs industry in Taiwan. Total returns to shareholders of 314% over the past three years.Reported Earnings • Aug 19First half 2022 earnings released: EPS: NT$0.18 (vs NT$0.43 loss in 1H 2021)First half 2022 results: EPS: NT$0.18 (up from NT$0.43 loss in 1H 2021). Revenue: NT$319.0m (up 9.3% from 1H 2021). Net income: NT$19.3m (up NT$58.6m from 1H 2021). Profit margin: 6.1% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Yau-Huei Wei was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 18First half 2021 earnings released: NT$0.43 loss per share (vs NT$1.05 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: NT$291.8m (up 29% from 1H 2020). Net loss: NT$39.2m (loss narrowed 56% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、UBI Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:6562 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20236491-1147N/A9/30/202365021-5177N/A6/30/20236514213148N/A3/31/20236424416165N/A12/31/20226344719183N/A9/30/202266064-42116N/A6/30/202268681-10350N/A3/31/202266552-8046N/A12/31/202164422-5742N/A9/30/2021577-1-6227N/A6/30/2021510-24-6812N/A3/31/2021484-49-128-33N/A12/31/2020458-74-188-79N/A9/30/2020467-149-286-90N/A6/30/2020476-223-385-102N/A3/31/2020478-233-554-165N/A12/31/2019480-242-724-228N/A9/30/2019459-242-768-278N/A6/30/2019438-242-812-327N/A3/31/2019431-241-685-278N/A12/31/2018424-241-558-229N/A9/30/2018412-213-447-191N/A6/30/2018400-185-337-152N/A3/31/2018366-176-299-153N/A12/31/2017333-167-261-153N/A9/30/2017335-204N/A-75N/A6/30/2017337-241N/A4N/A3/31/2017347-233N/A21N/A12/31/2016358-226N/A39N/A9/30/2016389-135N/A-17N/A6/30/2016421-43N/A-72N/A3/31/2016417-21N/A-119N/A12/31/20154132N/A-166N/A12/31/201440939N/A-76N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6562の予測収益成長が 貯蓄率 ( 1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6562の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6562の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6562の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6562の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6562の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/05/12 10:54終値2024/05/10 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋UBI Pharma Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 20Full year 2023 earnings released: EPS: NT$0.01 (vs NT$0.41 in FY 2022)Full year 2023 results: EPS: NT$0.01 (down from NT$0.41 in FY 2022). Revenue: NT$648.6m (up 2.3% from FY 2022). Net income: NT$803.0k (down 98% from FY 2022). Profit margin: 0.1% (down from 7.4% in FY 2022). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Apr 18Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$22.80, the stock trades at a trailing P/E ratio of 64.6x. Average trailing P/E is 48x in the Biotechs industry in Taiwan. Total loss to shareholders of 45% over the past year.
New Risk • Apr 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.20b (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (NT$3.20b market cap, or US$98.5m).
お知らせ • Mar 20UBI Pharma Inc., Annual General Meeting, Jun 06, 2024UBI Pharma Inc., Annual General Meeting, Jun 06, 2024.
New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
New Risk • Dec 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
Reported Earnings • Aug 17First half 2023 earnings released: EPS: NT$0.12 (vs NT$0.18 in 1H 2022)First half 2023 results: EPS: NT$0.12 (down from NT$0.18 in 1H 2022). Revenue: NT$335.7m (up 5.2% from 1H 2022). Net income: NT$13.8m (down 28% from 1H 2022). Profit margin: 4.1% (down from 6.1% in 1H 2022). The decrease in margin was driven by higher expenses.
New Risk • Aug 12New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.4% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.
Buying Opportunity • Jul 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be NT$44.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.
Buying Opportunity • Jun 16Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 22%. The fair value is estimated to be NT$44.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.
Reported Earnings • Apr 22Full year 2022 earnings released: EPS: NT$0.43 (vs NT$0.23 in FY 2021)Full year 2022 results: EPS: NT$0.43 (up from NT$0.23 in FY 2021). Revenue: NT$633.8m (down 1.6% from FY 2021). Net income: NT$47.2m (up 111% from FY 2021). Profit margin: 7.4% (up from 3.5% in FY 2021). The increase in margin was driven by lower expenses.
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$55.60, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 40x in the Biotechs industry in Taiwan. Total returns to shareholders of 509% over the past three years.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Yau-Huei Wei was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improved over the past weekAfter last week's 25% share price gain to NT$39.40, the stock trades at a trailing P/E ratio of 54.2x. Average trailing P/E is 35x in the Biotechs industry in Taiwan. Total returns to shareholders of 314% over the past three years.
Reported Earnings • Aug 19First half 2022 earnings released: EPS: NT$0.18 (vs NT$0.43 loss in 1H 2021)First half 2022 results: EPS: NT$0.18 (up from NT$0.43 loss in 1H 2021). Revenue: NT$319.0m (up 9.3% from 1H 2021). Net income: NT$19.3m (up NT$58.6m from 1H 2021). Profit margin: 6.1% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Yau-Huei Wei was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 18First half 2021 earnings released: NT$0.43 loss per share (vs NT$1.05 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: NT$291.8m (up 29% from 1H 2020). Net loss: NT$39.2m (loss narrowed 56% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth.